{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-24-000036","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.762860+00:00","generated_at":"2026-05-30T08:13:56.810731+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AbbVie Q3 EPS $3.00 adjusted (+1.7%), revenue $14.46B (+3.8%); raises 2024 guidance, increases dividend 5.8%","bullets":["Adjusted diluted EPS $3.00, up 1.7% YoY; GAAP EPS $0.88, down 12.0%.","Revenue $14.460B, +3.8% reported (+4.9% operational); Immunology $7.046B (+3.9%) led by Skyrizi (+50.8%) and Rinvoq (+45.3%).","Raises 2024 adjusted EPS guidance to $10.90-$10.94 from $10.67-$10.87.","Increases quarterly dividend 5.8% to $1.64/share, payable Feb 14, 2025 to holders of record Jan 15, 2025.","Completed acquisition of Cerevel, adding pipeline of complementary neuroscience assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-24-000036","json":"https://secwatch.observer/filing/0001551152-24-000036.json","markdown":"https://secwatch.observer/filing/0001551152-24-000036.md","text":"https://secwatch.observer/filing/0001551152-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000036/0001551152-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115224000036/abbv-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:13:56.810731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}